Description

Novoparin solution for injections 40 mg. syringe 0.4 ml. №2

Ingredients:

Novoparin solution for injections contains 40 mg of the active ingredient per 0.4 ml syringe. The main component of this medication is enoxaparin sodium, which belongs to a class of medications known as low molecular weight heparins.

Dosage:

The recommended dosage of Novoparin solution for injections is determined by the healthcare provider based on the patient’s condition, weight, and other factors. It is typically administered subcutaneously once or twice daily.

Indications:

Novoparin is indicated for the prevention of deep vein thrombosis (DVT) in patients undergoing surgery, particularly orthopedic procedures such as hip or knee replacement. It is also used for the treatment of DVT and pulmonary embolism.

Contraindications:

This medication is contraindicated in patients with active major bleeding, hypersensitivity to enoxaparin sodium, or a history of heparin-induced thrombocytopenia.

Directions:

Novoparin solution for injections should be administered as directed by a healthcare professional. The injection site should be rotated, and the injection should be given subcutaneously, avoiding areas with bruising or scars.

Scientific Evidence:

Studies have shown that enoxaparin, the active ingredient in Novoparin, is effective in preventing and treating thrombotic events. Research published in the Journal of Thrombosis and Haemostasis demonstrated the efficacy of enoxaparin in reducing the risk of DVT following orthopedic surgery.

Additional Information:

It is important to monitor for signs of bleeding while using Novoparin solution for injections. Patients should report any unusual bleeding or bruising to their healthcare provider. This medication should be stored at room temperature and protected from light.

Pharmacological Effects: Enoxaparin works by inhibiting the activity of certain clotting factors in the blood, thereby preventing the formation of blood clots. It has a more predictable anticoagulant response compared to unfractionated heparin, making it a preferred choice for many healthcare providers.

Clinical Trials: Clinical trials have shown that enoxaparin is as effective as unfractionated heparin in preventing DVT and has a lower risk of heparin-induced thrombocytopenia. A study published in the New England Journal of Medicine found that enoxaparin was associated with a lower incidence of recurrent thromboembolism in patients with acute coronary syndromes.